Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).
Highlights
The global Rheumatoid Arthritis (RA) Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Rheumatoid Arthritis (RA) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Rheumatoid Arthritis (RA) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Rheumatoid Arthritis (RA) Drugs in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Rheumatoid Arthritis (RA) Drugs include AbbVie, Roche, Merck, HEYL Chemisch-pharmazeutische Fabrik, Johnson & Johnson, Amgen, Inc., Pfizer, Bristol-Myers Squibb and UCB, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Rheumatoid Arthritis (RA) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rheumatoid Arthritis (RA) Drugs.
The Rheumatoid Arthritis (RA) Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Rheumatoid Arthritis (RA) Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rheumatoid Arthritis (RA) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
AbbVie
Roche
Merck
HEYL Chemisch-pharmazeutische Fabrik
Johnson & Johnson
Amgen, Inc.
Pfizer
Bristol-Myers Squibb
UCB
GSK
Sanofi
Abbott Laboratories
Teva Pharmaceutical
Segment by Type
NSAIDs
Analgesic Drugs
Corticosteroids
DMARDs
Biological Therapies
JAK-inhibitors
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rheumatoid Arthritis (RA) Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Rheumatoid Arthritis (RA) Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 NSAIDs
1.2.3 Analgesic Drugs
1.2.4 Corticosteroids
1.2.5 DMARDs
1.2.6 Biological Therapies
1.2.7 JAK-inhibitors
1.3 Market by Application
1.3.1 Global Rheumatoid Arthritis (RA) Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Rheumatoid Arthritis (RA) Drugs Market Perspective (2018-2029)
2.2 Rheumatoid Arthritis (RA) Drugs Growth Trends by Region
2.2.1 Global Rheumatoid Arthritis (RA) Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Rheumatoid Arthritis (RA) Drugs Historic Market Size by Region (2018-2023)
2.2.3 Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Region (2024-2029)
2.3 Rheumatoid Arthritis (RA) Drugs Market Dynamics
2.3.1 Rheumatoid Arthritis (RA) Drugs Industry Trends
2.3.2 Rheumatoid Arthritis (RA) Drugs Market Drivers
2.3.3 Rheumatoid Arthritis (RA) Drugs Market Challenges
2.3.4 Rheumatoid Arthritis (RA) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Rheumatoid Arthritis (RA) Drugs Players by Revenue
3.1.1 Global Top Rheumatoid Arthritis (RA) Drugs Players by Revenue (2018-2023)
3.1.2 Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Rheumatoid Arthritis (RA) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Rheumatoid Arthritis (RA) Drugs Revenue
3.4 Global Rheumatoid Arthritis (RA) Drugs Market Concentration Ratio
3.4.1 Global Rheumatoid Arthritis (RA) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Rheumatoid Arthritis (RA) Drugs Revenue in 2022
3.5 Rheumatoid Arthritis (RA) Drugs Key Players Head office and Area Served
3.6 Key Players Rheumatoid Arthritis (RA) Drugs Product Solution and Service
3.7 Date of Enter into Rheumatoid Arthritis (RA) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Rheumatoid Arthritis (RA) Drugs Breakdown Data by Type
4.1 Global Rheumatoid Arthritis (RA) Drugs Historic Market Size by Type (2018-2023)
4.2 Global Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Type (2024-2029)
5 Rheumatoid Arthritis (RA) Drugs Breakdown Data by Application
5.1 Global Rheumatoid Arthritis (RA) Drugs Historic Market Size by Application (2018-2023)
5.2 Global Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Rheumatoid Arthritis (RA) Drugs Market Size (2018-2029)
6.2 North America Rheumatoid Arthritis (RA) Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Rheumatoid Arthritis (RA) Drugs Market Size by Country (2018-2023)
6.4 North America Rheumatoid Arthritis (RA) Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Rheumatoid Arthritis (RA) Drugs Market Size (2018-2029)
7.2 Europe Rheumatoid Arthritis (RA) Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Rheumatoid Arthritis (RA) Drugs Market Size by Country (2018-2023)
7.4 Europe Rheumatoid Arthritis (RA) Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Size (2018-2029)
8.2 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Rheumatoid Arthritis (RA) Drugs Market Size (2018-2029)
9.2 Latin America Rheumatoid Arthritis (RA) Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Rheumatoid Arthritis (RA) Drugs Market Size by Country (2018-2023)
9.4 Latin America Rheumatoid Arthritis (RA) Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Size (2018-2029)
10.2 Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Rheumatoid Arthritis (RA) Drugs Introduction
11.1.4 AbbVie Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.1.5 AbbVie Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Rheumatoid Arthritis (RA) Drugs Introduction
11.2.4 Roche Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.2.5 Roche Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck Rheumatoid Arthritis (RA) Drugs Introduction
11.3.4 Merck Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.3.5 Merck Recent Development
11.4 HEYL Chemisch-pharmazeutische Fabrik
11.4.1 HEYL Chemisch-pharmazeutische Fabrik Company Detail
11.4.2 HEYL Chemisch-pharmazeutische Fabrik Business Overview
11.4.3 HEYL Chemisch-pharmazeutische Fabrik Rheumatoid Arthritis (RA) Drugs Introduction
11.4.4 HEYL Chemisch-pharmazeutische Fabrik Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.4.5 HEYL Chemisch-pharmazeutische Fabrik Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Rheumatoid Arthritis (RA) Drugs Introduction
11.5.4 Johnson & Johnson Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.5.5 Johnson & Johnson Recent Development
11.6 Amgen, Inc.
11.6.1 Amgen, Inc. Company Detail
11.6.2 Amgen, Inc. Business Overview
11.6.3 Amgen, Inc. Rheumatoid Arthritis (RA) Drugs Introduction
11.6.4 Amgen, Inc. Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.6.5 Amgen, Inc. Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Rheumatoid Arthritis (RA) Drugs Introduction
11.7.4 Pfizer Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.7.5 Pfizer Recent Development
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Detail
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Rheumatoid Arthritis (RA) Drugs Introduction
11.8.4 Bristol-Myers Squibb Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.8.5 Bristol-Myers Squibb Recent Development
11.9 UCB
11.9.1 UCB Company Detail
11.9.2 UCB Business Overview
11.9.3 UCB Rheumatoid Arthritis (RA) Drugs Introduction
11.9.4 UCB Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.9.5 UCB Recent Development
11.10 GSK
11.10.1 GSK Company Detail
11.10.2 GSK Business Overview
11.10.3 GSK Rheumatoid Arthritis (RA) Drugs Introduction
11.10.4 GSK Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.10.5 GSK Recent Development
11.11 Sanofi
11.11.1 Sanofi Company Detail
11.11.2 Sanofi Business Overview
11.11.3 Sanofi Rheumatoid Arthritis (RA) Drugs Introduction
11.11.4 Sanofi Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.11.5 Sanofi Recent Development
11.12 Abbott Laboratories
11.12.1 Abbott Laboratories Company Detail
11.12.2 Abbott Laboratories Business Overview
11.12.3 Abbott Laboratories Rheumatoid Arthritis (RA) Drugs Introduction
11.12.4 Abbott Laboratories Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.12.5 Abbott Laboratories Recent Development
11.13 Teva Pharmaceutical
11.13.1 Teva Pharmaceutical Company Detail
11.13.2 Teva Pharmaceutical Business Overview
11.13.3 Teva Pharmaceutical Rheumatoid Arthritis (RA) Drugs Introduction
11.13.4 Teva Pharmaceutical Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.13.5 Teva Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
AbbVie
Roche
Merck
HEYL Chemisch-pharmazeutische Fabrik
Johnson & Johnson
Amgen, Inc.
Pfizer
Bristol-Myers Squibb
UCB
GSK
Sanofi
Abbott Laboratories
Teva Pharmaceutical
*If Applicable.